JP2010540661A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010540661A5 JP2010540661A5 JP2010528172A JP2010528172A JP2010540661A5 JP 2010540661 A5 JP2010540661 A5 JP 2010540661A5 JP 2010528172 A JP2010528172 A JP 2010528172A JP 2010528172 A JP2010528172 A JP 2010528172A JP 2010540661 A5 JP2010540661 A5 JP 2010540661A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- enantiomerically enriched
- group
- nilvadipine
- condition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims 7
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 7
- 230000003942 amyloidogenic effect Effects 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 229960005366 nilvadipine Drugs 0.000 claims 7
- 230000036772 blood pressure Effects 0.000 claims 5
- 210000004556 brain Anatomy 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 4
- 206010029350 Neurotoxicity Diseases 0.000 claims 2
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 230000006933 amyloid-beta aggregation Effects 0.000 claims 2
- 230000003796 beauty Effects 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 239000003889 eye drop Substances 0.000 claims 2
- 229940012356 eye drops Drugs 0.000 claims 2
- 239000007937 lozenge Substances 0.000 claims 2
- 230000007388 microgliosis Effects 0.000 claims 2
- 230000007135 neurotoxicity Effects 0.000 claims 2
- 231100000228 neurotoxicity Toxicity 0.000 claims 2
- -1 sachets Substances 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 241000238367 Mya arenaria Species 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 210000005252 bulbus oculi Anatomy 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- 208000021822 hypotensive Diseases 0.000 claims 1
- 230000001077 hypotensive effect Effects 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 231100000682 maximum tolerated dose Toxicity 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 235000012431 wafers Nutrition 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97795307P | 2007-10-05 | 2007-10-05 | |
| US60/977,953 | 2007-10-05 | ||
| US4610908P | 2008-04-18 | 2008-04-18 | |
| US61/046,109 | 2008-04-18 | ||
| PCT/US2008/078786 WO2009046323A1 (en) | 2007-10-05 | 2008-10-03 | Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010540661A JP2010540661A (ja) | 2010-12-24 |
| JP2010540661A5 true JP2010540661A5 (enExample) | 2011-11-17 |
| JP5411145B2 JP5411145B2 (ja) | 2014-02-12 |
Family
ID=40523447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528172A Expired - Fee Related JP5411145B2 (ja) | 2007-10-05 | 2008-10-03 | （−）−ニルバジピンエナンチオマーによってアミロイド沈着、アミロイド神経毒性、およびミクログリオーシスを減少させる方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8236346B2 (enExample) |
| EP (1) | EP2214666B1 (enExample) |
| JP (1) | JP5411145B2 (enExample) |
| KR (1) | KR101417200B1 (enExample) |
| CN (1) | CN101883564B (enExample) |
| AU (1) | AU2008308519B2 (enExample) |
| BR (1) | BRPI0817516A2 (enExample) |
| CA (1) | CA2701620C (enExample) |
| DK (1) | DK2214666T3 (enExample) |
| ES (1) | ES2449594T3 (enExample) |
| MX (1) | MX2010003669A (enExample) |
| NZ (1) | NZ584729A (enExample) |
| PL (1) | PL2214666T3 (enExample) |
| RU (1) | RU2490014C2 (enExample) |
| TW (1) | TWI500422B (enExample) |
| WO (1) | WO2009046323A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140286910A1 (en) * | 2013-03-19 | 2014-09-25 | Nikolai Tankovich | Stem cells and methods incorporating environmental factors as a means for enhancing stem cell proliferation and plasticity |
| CN112826794B (zh) | 2019-11-06 | 2022-02-11 | 上海交通大学医学院 | 一种靶向修复神经血管病变的纳米复合物及其制备与应用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4338322A (en) | 1975-07-02 | 1982-07-06 | Fujisawa Pharmaceutical Co., Ltd. | 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same |
| JPS6038322A (ja) | 1983-08-11 | 1985-02-27 | Fujisawa Pharmaceut Co Ltd | ジヒドロピリジンａ物質含有易溶性固形製剤 |
| JPS61129140A (ja) | 1984-11-27 | 1986-06-17 | Nitto Electric Ind Co Ltd | 医薬組成物 |
| GB8431119D0 (en) | 1984-12-10 | 1985-01-16 | Fujisawa Pharmaceutical Co | Anti-arteriosclerotic composition |
| US4940556A (en) | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US5114946A (en) | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
| ES2043719T3 (es) | 1987-06-12 | 1994-01-01 | American Cyanamid Co | Administracion de farmacos por via percutanea. |
| US5045553A (en) | 1987-06-24 | 1991-09-03 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter |
| US4820720A (en) | 1987-08-24 | 1989-04-11 | Alza Corporation | Transdermal drug composition with dual permeation enhancers |
| US5508413A (en) * | 1987-08-27 | 1996-04-16 | Fujisawa Pharmaceutical Co., Ltd. | (+)-5-isopropyl 3-methyl 2-cyano-6 methyl-4-(3-nitrophenyl)-1, 4-dihydropyridine-3, 5-dicarboxylate |
| ES2037179T3 (es) | 1987-11-25 | 1993-06-16 | American Cyanamid Company | Sistema de liberacion sostenida (controlada) para bloqueadores de canales de calcio de dihidropiridina. |
| US5160734A (en) | 1987-11-25 | 1992-11-03 | American Cyanamid Company | Sustained release delivery system for substituted dihydropyridine calcium channel blockers |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| JP2718105B2 (ja) | 1988-10-27 | 1998-02-25 | 藤沢薬品工業株式会社 | （＋）−２−シアノ−６−メチル−４−（３−ニトロフェニル）−１，４−ジヒドロピリジン−３，５−ジカルボン酸５−イソプロピル３−メチルの光安定性結晶 |
| WO1990011761A1 (en) | 1989-03-31 | 1990-10-18 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
| JPH0381262A (ja) | 1989-08-23 | 1991-04-05 | Yamanouchi Pharmaceut Co Ltd | ジヒドロピリジン系カルシウム拮抗薬の光学活性体の製造法 |
| JP2867462B2 (ja) | 1989-09-12 | 1999-03-08 | 藤沢薬品工業株式会社 | 経皮吸収用製剤 |
| JP2920956B2 (ja) | 1989-10-06 | 1999-07-19 | 藤沢薬品工業株式会社 | ニルバジピン含有持続性錠剤 |
| US5258393A (en) | 1990-02-21 | 1993-11-02 | Fujisawa Pharmaceutical Co., Ltd. | Use of a dihydropyridine compound for improving inner ear microcirculation |
| EP0557290A1 (en) | 1990-08-23 | 1993-09-01 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss |
| WO1993005770A1 (fr) | 1991-09-20 | 1993-04-01 | Fujisawa Pharmaceutical Co., Ltd. | Preparation a longue duree d'action |
| JPH05139974A (ja) | 1991-11-26 | 1993-06-08 | Fujisawa Pharmaceut Co Ltd | ジヒドロピリジンａ物質含有易溶性固体分散体の製造法 |
| US5834496A (en) | 1991-12-02 | 1998-11-10 | Sepracor, Inc. | Methods for treating hypertension using optically pure S(-) felodipine |
| DE4141646A1 (de) | 1991-12-17 | 1993-06-24 | Klinge Co Chem Pharm Fab | Arzneimittelkombination mit synergistischer wirkung, verfahren zu seiner herstellung und seine verwendung |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| DE4229805A1 (de) | 1992-09-07 | 1994-03-24 | Werner E G Prof Dr Mueller | Kalzium-Kanal-Antagonisten oder deren Derivate zur Herstellung eines Arzneimittels zur Bekämpfung von Erkrankungen, die durch Prion-Proteine oder Prion-analoge Proteine ausgelöst werden |
| US5721263A (en) | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| CA2125251C (en) | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| AU682192B2 (en) * | 1993-06-30 | 1997-09-25 | Fujisawa Pharmaceutical Co., Ltd. | Encapsulated medicine |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| JP3541389B2 (ja) | 1996-04-26 | 2004-07-07 | 藤沢薬品工業株式会社 | ジヒドロピリジン化合物を含有する眼組織末梢循環改善剤 |
| US6271259B1 (en) | 1996-05-07 | 2001-08-07 | Ito En, Ltd. | Method for improving the brain function, inhibiting glutamate excitotoxicity and rescuing from neuronal death |
| KR100222306B1 (ko) | 1996-11-20 | 1999-10-01 | 이병언 | 닐바디핀 속효성 고형제제 및 이의 제조방법 |
| US6541479B1 (en) * | 1997-12-02 | 2003-04-01 | Massachusetts College Of Pharmacy | Calcium channel blockers |
| CA2318806A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding agents that modulate the 5-ht transporter |
| JP2002517440A (ja) | 1998-06-08 | 2002-06-18 | アドバンスド メディスン インコーポレーテッド | 新規カルシウムチャンネル薬物および用途 |
| RU2243768C2 (ru) | 1998-07-10 | 2005-01-10 | Новартис Аг | Гипотензивная комбинация валсартана и блокатора кальциевых каналов |
| WO2001064250A1 (en) | 2000-03-03 | 2001-09-07 | Fujisawa Pharmaceutical Co., Ltd. | Remedies for malignant tumor-concomitant neurosis and azoor or analogous diseases thereof |
| WO2001076598A1 (en) | 2000-04-11 | 2001-10-18 | Sankyo Company, Limited | Stabilized pharmaceutical compositions containing calcium channel blockers |
| JP2001335483A (ja) | 2000-05-30 | 2001-12-04 | Nichiko Pharmaceutical Co Ltd | ニルバジピン含有製剤 |
| CA2415826A1 (en) | 2000-07-27 | 2002-02-07 | Pharmacia Corporation | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| JP3968687B2 (ja) | 2000-09-13 | 2007-08-29 | 東和薬品株式会社 | 易吸収性ニルバジピン錠 |
| JP3470096B2 (ja) | 2000-09-19 | 2003-11-25 | 沢井製薬株式会社 | ニルバジピン含有易溶性固形製剤およびその製造法 |
| JP2004516269A (ja) | 2000-12-19 | 2004-06-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | チエノピリミジンおよび抗血栓剤、カルシウム拮抗剤、プロスタグランジンまたはプロスタグランジン誘導体を含有する医薬製剤 |
| BR0115995A (pt) | 2000-12-19 | 2004-01-13 | Merck Patent Gmbh | Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina |
| US7083642B2 (en) | 2000-12-22 | 2006-08-01 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
| CA2333494A1 (en) | 2001-02-01 | 2002-08-01 | Vasogen Ireland Limited | Blood brain barrier modulation |
| MXPA03010843A (es) | 2001-05-25 | 2004-02-17 | Schering Corp | Uso de derivados con azetidinona en el tratamiento de enfermedad de alzheimer. |
| EP1426051B1 (en) | 2001-09-11 | 2008-07-16 | Asahi Kasei Pharma Corporation | Medicinal composition for prevention of or treatment for cerebrovascular disorder |
| PL219032B1 (pl) | 2002-05-17 | 2015-03-31 | Novartis Ag | Kompozycja farmaceutyczna zawierająca alskiren, amlodypinę i hydrochlortiazyd, kombinacja zawierająca te składniki, zastosowanie wspomnianej kombinacji oraz zestaw handlowy zawierający wspomnianą kombinację |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| AR040017A1 (es) | 2002-05-17 | 2005-03-09 | Novartis Ag | Combinacion de compuestos organicos |
| JP2003146878A (ja) | 2002-11-22 | 2003-05-21 | Sawai Pharmaceutical Co Ltd | ニルバジピン含有易溶性固形製剤およびその製造法 |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| JP2006512417A (ja) | 2002-12-24 | 2006-04-13 | ニューロケム （インターナショナル） リミテッド | β−アミロイド関連疾患の治療のための治療用製剤 |
| ES2334029T3 (es) * | 2003-05-15 | 2010-03-04 | Roskamp Research Llc | Procedimiento para producir medicamentos para reducir la deposicion de amiloide, la neurotoxicidad de amiloide y la microgliosis. |
| JP2004002460A (ja) | 2003-07-29 | 2004-01-08 | Towa Yakuhin Kk | 易吸収性ニルバジピン錠の製造法 |
| WO2009046338A1 (en) * | 2007-10-05 | 2009-04-09 | Roskamp Research Llc | Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer |
-
2008
- 2008-10-03 DK DK08836256.1T patent/DK2214666T3/da active
- 2008-10-03 CA CA2701620A patent/CA2701620C/en not_active Expired - Fee Related
- 2008-10-03 JP JP2010528172A patent/JP5411145B2/ja not_active Expired - Fee Related
- 2008-10-03 BR BRPI0817516-0A patent/BRPI0817516A2/pt not_active Application Discontinuation
- 2008-10-03 PL PL08836256T patent/PL2214666T3/pl unknown
- 2008-10-03 TW TW097138351A patent/TWI500422B/zh not_active IP Right Cessation
- 2008-10-03 EP EP08836256.1A patent/EP2214666B1/en active Active
- 2008-10-03 ES ES08836256.1T patent/ES2449594T3/es active Active
- 2008-10-03 CN CN200880118761XA patent/CN101883564B/zh not_active Expired - Fee Related
- 2008-10-03 MX MX2010003669A patent/MX2010003669A/es active IP Right Grant
- 2008-10-03 WO PCT/US2008/078786 patent/WO2009046323A1/en not_active Ceased
- 2008-10-03 AU AU2008308519A patent/AU2008308519B2/en not_active Ceased
- 2008-10-03 RU RU2010117634/15A patent/RU2490014C2/ru active
- 2008-10-03 US US12/245,354 patent/US8236346B2/en not_active Expired - Fee Related
- 2008-10-03 KR KR1020107009874A patent/KR101417200B1/ko not_active Expired - Fee Related
- 2008-10-03 NZ NZ584729A patent/NZ584729A/xx not_active IP Right Cessation
-
2010
- 2010-02-01 US US12/697,436 patent/US8236347B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025024102A (ja) | 神経障害および神経障害の処置方法 | |
| JP7781768B2 (ja) | 神経学的および精神障害の治療方法 | |
| JP2010518122A5 (enExample) | ||
| NZ588505A (en) | Dosing regimen for a selective S1P1 receptor agonist (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one | |
| JP2013544887A5 (enExample) | ||
| JP2014506321A5 (enExample) | ||
| JP2015526458A5 (enExample) | ||
| EP2254598A2 (en) | Alpha 7 nicotinic agonists and antipsychotics | |
| WO2017031319A1 (en) | Noradrenergic drug treatment of obstructive sleep apnea | |
| JP2019532926A5 (enExample) | ||
| JP2021526507A (ja) | 発作により誘発される突然死を処置するための組成物および方法 | |
| ES2426008T5 (es) | Tratamiento de síntomas de la enfermedad de Parkinson con ligandos del receptor de histamina H3 de alquilaminas no imidazólicas | |
| FR2974729A1 (fr) | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent | |
| US10682343B2 (en) | Snoring treatment | |
| JP2007506801A (ja) | モダフィニルおよび他の薬剤を含んでなる製薬学的組成物 | |
| JP2010540661A5 (enExample) | ||
| JP2011500589A5 (enExample) | ||
| EP3813816B1 (en) | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome | |
| CA2525970A1 (en) | Use of nilvadipine for reducing amyloid deposition, amyloid neurotoxicity and microgliosis | |
| AU2005314935A1 (en) | Preventive or therapeutic agent for sleep disorder | |
| JP2005505570A (ja) | Ｐｄｅ阻害剤及びロイコトリエン受容体拮抗物質の複合薬 | |
| US20180193289A1 (en) | Prototypical molecular pharmacologic profile of fendiline against neurodegenerative and neurodevelopmental diseases | |
| JP2013518061A5 (enExample) | ||
| CN110267657B (zh) | 氨基甲酸酯化合物用于预防、缓解或治疗震颤或震颤综合征的用途 | |
| RU2009141168A (ru) | Способы и композиции, содержащие дезвенлафаксин или дулоксетин, для лечения расстройств дыхания во время сна |